FRANKLIN LAKES, N.J., Sept. 26, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch1 of the first automated phenotypic test to detect and classify carbapenemase-producing organisms (CPO). Available as part of the BD Phoenix™ automated microbiology system in Europe, the new BD Phoenix™ CPO detect test... Read more
FRANKLIN LAKES, N.J. and SIZIANO, Italy, Sept. 20, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Euroclone (Euroclone Diagnostica Srl) today announced a development and global distribution agreement for molecular tests to detect emerging sexually-transmitted pathogens. According to the World Health Organization, more than 1 million... Read more
FRANKLIN LAKES, N.J., Sept. 12, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of BD Rhapsody, a platform for single cell analysis with the ability to detect rare molecules responsible for biological diversity that are often missed with whole transcriptome profiling. Developed using the company’s... Read more
FRANKLIN LAKES, N.J., Sept. 8, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the Morgan Stanley Global Healthcare Conference 2017 on Tuesday, September 12, 2017, at 9:10 a.m. EDT. A live webcast of BD’s presentation can be accessed from the BD... Read more
MURRAY HILL, N.J. and FRANKLIN LAKES, N.J., Aug. 8, 2017 /PRNewswire/ — C. R. Bard, Inc. (NYSE: BCR) (“Bard”) and Becton, Dickinson and Company (NYSE: BDX) (“BD”) today announced the results of Bard’s special meeting of shareholders, held on August 8, 2017 and at which a quorum was present, for Bard shareholders to consider and vote... Read more
BD FACSLyric™ Flow Cytometer System with BD Multitest™ Assays Offers Reliability and Consistency Jul 19, 2017 FRANKLIN LAKES, N.J., July 19, 2017 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the BD FACSLyric™... Read more
NEW YORK, NY, June 29, 2017 – Enzo Biochem Inc. (NYSE: ENZ) reported today that a federal judge for the U.S. District Court for the District of Delaware has entered an order in the actions entitled Enzo Life Sciences, Inc. v. Gen-Probe Incorporated, Enzo Life Sciences, Inc. v. Hologic, Inc., Enzo Life Sciences, Inc. v. Roche Molecular... Read more
Leaders in flow cytometry tools collaborate to deliver cloud data management capabilities and streamline experimental execution June 13, 2017 03:59 AM Pacific Daylight Time ASHLAND, Ore. & FRANKLIN LAKES, N.J.–(BUSINESS WIRE)–FlowJo, LLC, a life science informatics and data analysis company with 20 years of experience in software for analyzing single-cell data, and global medical technology... Read more
FRANKLIN LAKES, N.J., May 19, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (BDX) announced today that, in connection with its previously announced offers to exchange (the “Exchange Offers”) any and all outstanding 4.400% Notes due 2021, 3.000% Notes due 2026 and 6.700% Notes due 2026 (collectively, the “Bard Notes”) issued by C. R. Bard, Inc.... Read more
FRANKLIN LAKES, N.J., May 15, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (BDX), a leading global medical technology company, announced today that it will present at the following upcoming investor healthcare conferences: Bank of America Merrill Lynch 2017 Healthcare Conference May 17, 2017 11:40 a.m. EDT Jefferies 2017 Global Healthcare Conference June 8, 2017 9:00 a.m.... Read more